Mobile

A study to evaluate the safety, tolerability and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes who are already taking Metformin (licensed drug)

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003670-11

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- After 24 weeks, to assess the effect of the addition of treatment with MK- 3102 compared to placebo on A1C. - To assess the safety and tolerability of MK-3102.

Critère d'inclusion

  • Type 2 diabetes mellitus

Liens